Cargando…
Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381623/ https://www.ncbi.nlm.nih.gov/pubmed/34437985 http://dx.doi.org/10.1016/j.jaad.2021.08.031 |
| _version_ | 1783741406673633280 |
|---|---|
| author | Waldman, Reid Alexander Grant-Kels, Jane M. |
| author_facet | Waldman, Reid Alexander Grant-Kels, Jane M. |
| author_sort | Waldman, Reid Alexander |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8381623 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier on behalf of the American Academy of Dermatology, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83816232021-08-23 Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations Waldman, Reid Alexander Grant-Kels, Jane M. J Am Acad Dermatol A Clinician's Perspective Published by Elsevier on behalf of the American Academy of Dermatology, Inc. 2021-11 2021-08-23 /pmc/articles/PMC8381623/ /pubmed/34437985 http://dx.doi.org/10.1016/j.jaad.2021.08.031 Text en © 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | A Clinician's Perspective Waldman, Reid Alexander Grant-Kels, Jane M. Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations |
| title | Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations |
| title_full | Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations |
| title_fullStr | Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations |
| title_full_unstemmed | Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations |
| title_short | Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations |
| title_sort | dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger rna covid-19 vaccine dose: a critical appraisal of recent food and drug administration and advisory committee on immunization practices recommendations |
| topic | A Clinician's Perspective |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381623/ https://www.ncbi.nlm.nih.gov/pubmed/34437985 http://dx.doi.org/10.1016/j.jaad.2021.08.031 |
| work_keys_str_mv | AT waldmanreidalexander dermatologypatientsonbiologicsandcertainothersystemictherapiesshouldreceiveaboostermessengerrnacovid19vaccinedoseacriticalappraisalofrecentfoodanddrugadministrationandadvisorycommitteeonimmunizationpracticesrecommendations AT grantkelsjanem dermatologypatientsonbiologicsandcertainothersystemictherapiesshouldreceiveaboostermessengerrnacovid19vaccinedoseacriticalappraisalofrecentfoodanddrugadministrationandadvisorycommitteeonimmunizationpracticesrecommendations |